Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT06047262

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06047262
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, France, Germany, Switzerland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06047262. Randomized; double masking; primary purpose treatment. Start 2024-07-09 (actual); primary completion 2028-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
Acronym
Dapan-Dia
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dapansutrile
Intervention (Drug)
Placebo
Lead sponsor
Marc Donath (class: other)
Collaborator
European Union (class: other)
Collaborator
State Secretariat for Education Research and Innovation, Switzerland (class: other)
Collaborator
Olatec Therapeutics, Inc. (class: industry)
Collaborator
Departement Klinische Forschung Universität Basel (class: not stated)
Collaborator
CTU Kantonsspital Baden (class: not stated)

Record details

Record id
cardio:ct-nct06047262
Content hash
b32a3046cb5c6ddcd60c185364708ac77da16fb51bf4cd2b75be5f521550134f